Magazine Article | January 1, 2017

Companies To Watch: Ritter Pharmaceuticals

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

On a mission to develop the first FDA-approved, durable-efficacy therapeutic for lactose intolerance

Cofounded by its namesake, Andrew Ritter, Ritter Pharmaceuticals is developing a treatment — not merely a symptom reliever — for lactose intolerance, which has plagued Ritter himself since childhood. It is entering Phase 3 development with a “gut-microbiome modifier” targeted at the condition, and it is in preclinical testing exploring microbiome-based treatments for metabolic syndrome, liver disease, cancer, and other gastrointestinal conditions.